LEASELease • November 10th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances)
AMENDMENT TO AMENDED AND RESTATED AGREEMENTAmended and Restated Agreement • November 10th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • New York
This Amendment to Amended and Restated Agreement (this “Amendment”) is entered into as of August 9, 2021 (the “Amendment Effective Date”) by and between Finch Therapeutics, Inc., a Delaware corporation having its principal office at 200 Inner Belt Road, 4th Floor, Somerville, Massachusetts 02143 (“Finch”), and Takeda Development Center Americas, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, having its principal office at 95 Hayden Avenue, Lexington, MA 02421 (“Takeda”).
